BMC Cancer (Jun 2010)

Elevated MED28 expression predicts poor outcome in women with breast cancer

  • Horvath Steve,
  • Li Ai,
  • Elshimali Yahya,
  • Maresh Erin L,
  • Yoon Nam K,
  • Seligson David B,
  • Chia David,
  • Goodglick Lee

DOI
https://doi.org/10.1186/1471-2407-10-335
Journal volume & issue
Vol. 10, no. 1
p. 335

Abstract

Read online

Abstract Background MED28 (also known as EG-1 and magicin) has been implicated in transcriptional control, signal regulation, and cell proliferation. MED28 has also been associated with tumor progression in in vitro and in vivo models. Here we examined the association of MED28 expression with human breast cancer progression. Methods Expression of MED28 protein was determined on a population basis using a high-density tissue microarray consisting of 210 breast cancer patients. The association and validation of MED28 expression with histopathological subtypes, clinicopathological variables, and disease outcome was assessed. Results MED28 protein expression levels were increased in ductal carcinoma in situ and invasive ductal carcinoma of the breast compared to non-malignant glandular and ductal epithelium. Moreover, MED28 was a predictor of disease outcome in both univariate and multivariate analyses with higher expression predicting a greater risk of disease-related death. Conclusions We have demonstrated that MED28 expression is increased in breast cancer. In addition, although the patient size was limited (88 individuals with survival information) MED28 is a novel and strong independent prognostic indicator of survival for breast cancer.